Group 1 - The company, Rhine Biotech (002166.SZ), announced a notice regarding the lifting of restrictions on the non-public issuance of shares [1] - A total of 165 million shares will be released from restrictions, accounting for 22.31% of the company's total share capital [1] - There is one shareholder involved in this lifting of restrictions, and the shares will be tradable starting from September 5, 2025 [1]

Group 1 - The company, Rhine Biotech (002166.SZ), announced the lifting of restrictions on the issuance of non-publicly offered shares, allowing for the circulation of 165 million shares, which accounts for 22.31% of the total share capital [1] - The number of shareholders involved in this lifting of restrictions is one [1] - The shares will be available for public trading starting from September 5, 2025 [1]

除限售股东共计 1 名。 一、本次解除限售股份的基本情况 （一）解除限售股份基本情况 经中国证券监督管理委员会《关于核准桂林莱茵生物科技股份有限公司非公 开发行股票的批复》（证监许可[2021]2843 号）核准，并经深圳证券交易所同意， 桂林莱茵生物科技股份有限公司（以下简称"公司"或"本公司"）向控股股东、 实际控制人秦本军先生非公开发行人民币普通股（A 股）165,470,085 股（以下 简称"本次非公开发行股份"），发行价格为 5.85 元/股，本次非公开发行新增 股份于 2022 年 9 月 5 日在深圳证券交易所上市。本次非公开发行的发行对象、 发行数量、限售期等具体情况如下： | 发行对象 | 认购股份数（股） 锁定期限（月） | | --- | --- | | 秦本军 | 165,470,085 36 | （二）本次申请解除限售股份的数量调整情况 桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2025-053 桂林莱茵生物科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 本次非 ...

桂林莱茵生物科技股份有限公司 关于非公开发行限售股份解除限售上市流通的提示性公告 证券代码：002166 证券简称：莱茵生物 公告编号：2025-053 桂林莱茵生物科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次解除限售的股份数量为 165,470,085 股，占公司总股本 22.31%，解 除限售股东共计 1 名。 2、本次解除限售股份可上市流通日期为 2025 年 9 月 5 日。 一、本次解除限售股份的基本情况 桂林莱茵生物科技股份有限公司 二、申请解除股份限售股东履行承诺情况 截至本公告披露之日，秦本军先生的承诺事项及履行情况如下： | 承诺人 | 承诺类型 | 承诺内容 | 承诺时间 | | 承诺 | 履行 | | --- | --- | --- | --- | --- | --- | --- | | | | | | | 期限 | 情况 | | | | 公司控股股东、实际控制人秦本军， | | | | | | | | 作为莱茵生物 2022 年非公开发行股票 | | | | | | | | 的认购人，承诺如下： ...

光大证券股份有限公司关于 桂林莱茵生物科技股份有限公司 非公开发行限售股份解除限售上市流通的核查意见 光大证券股份有限公司（以下简称"光大证券"或"保荐机构"）作为桂林莱 茵生物科技股份有限公司（以下简称"莱茵生物"或"公司"）2020年非公开发行 股票项目的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所 股票上市规则》《深圳证券交易所上市公司自律监管指引第13号——保荐业务》等 有关规定，对莱茵生物非公开发行限售股份解除限售上市流通事项进行了核查，核 查情况及意见如下： 一、本次解除限售股份的基本情况 （一）解除限售股份基本情况 经中国证券监督管理委员会证监许可[2021]2843 号文《关于核准桂林莱茵生物 科技股份有限公司非公开发行股票的批复》核准，并经深圳证券交易所同意，公司 向控股股东、实际控制人秦本军先生非公开发行人民币普通股（A 股）165,470,085 股（以下简称"本次非公开发行股份"），发行价格为 5.85 元/股，本次非公开发 行新增股份于 2022年 9 月5 日在深圳证券交易所上市。本次非公开发行的发行对象、 发行数量、限售期等具体情况如下： | 发行对象 | 认购 ...

Core Viewpoint - Guilin Rhein Biotech Co., Ltd. reported a sales revenue growth of over 15% in the first half of 2025, but profits were under pressure due to industry competition, increased depreciation, and tariffs [1]. Group 1: Business and Performance - The company’s sales revenue growth exceeded 15% in the first half of 2025, but profits faced challenges from competitive pressures, rising depreciation costs, and tariffs [1]. - The company’s Vice General Manager and Board Secretary, Luo Huayang, participated in an online communication with nine institutions, including Zheshang Securities and Tianfeng Securities, to discuss operational performance [1]. Group 2: Raw Material and Product Price Trends - The purchase price of monk fruit raw materials is expected to remain stable this year, while the price of stevia raw materials is anticipated to be similar to last year [2]. - Some specifications of stevia products have seen slight price declines due to industry competition, but raw material costs are expected to support price stability [2]. - The price of monk fruit extracts is projected to rise as raw material prices recover [2]. Group 3: Product Development and Market Position - Rhein Biotech holds exclusive technology for the industrialization of stevia glycoside RM2, which is noted for its good taste, compatibility, and relatively controllable costs [2]. - The domestic certification for RM2 is dependent on government approval, while it has already received GRAS certification from the FDA in the U.S. and is in discussions with clients for cooperation [2]. - The company expects its synthetic biology workshop capacity to meet market demand within the next 2-3 years [2]. Group 4: Industrial Hemp Business - Despite potential policy adjustments regarding hemp by the U.S. President, there has not been a significant market recovery [2]. - The Indiana factory has been transformed into a comprehensive extraction facility, and the company will actively follow up if demand for industrial hemp revives [2]. Group 5: Competitive Advantages and Future Outlook - Rhein Biotech enhances its competitiveness through technological innovation and expanding application scenarios, particularly in synthetic biology and emerging markets like pet nutrition [2]. - The utilization rate of the new stevia extraction factory is expected to reach 40-50% for the year, with a significant increase anticipated after new raw materials are launched in September [2]. - The Indiana factory is positioned to navigate complex trade environments, focusing on natural sweeteners and leveraging local raw material procurement for supply chain security [2]. - The company anticipates a positive shift in operational performance in the third and fourth quarters of 2025, as trade policy uncertainties diminish and new products are launched [2].

Group 1: Raw Material Prices and Trends - The acquisition prices for core products, Luo Han Guo and Stevia, are expected to remain stable this year due to stable planting areas and yields [2][3] - The price of Stevia products has slightly decreased due to increased competition, but this is viewed as a short-term trend as raw material costs have limited downward potential [3][4] - Luo Han Guo extract prices are anticipated to rise further based on raw material price fluctuations [4][6] Group 2: RM2 Product Overview - RM2 is a unique steviol glycoside that offers superior taste, stability, and solubility compared to existing products like RD and RM [4][6] - RM2 has excellent compatibility with other sweeteners, allowing for diverse applications in baking and other food products [4][6] - The production cost of RM2 is controllable due to the advantages in raw material production, providing a cost advantage over traditional extraction methods [4][6] Group 3: Market Position and Competitive Advantage - RM2 is currently exclusive to the company, with significant barriers for competitors due to the need for specific technology and lengthy safety reviews [6][10] - The company has made substantial progress in product development and market expansion, particularly in emerging markets like pet nutrition and animal feed [10][11] - The company aims to leverage continuous innovation and differentiation to maintain a competitive edge in the natural sweetener market [10][11] Group 4: Production Capacity and Future Outlook - The new production facility in Indiana is expected to meet market demand over the next 2-3 years, with production capacity utilization projected to reach 40-50% by year-end [11][12] - The company anticipates a sales revenue growth of over 15% in the first half of the year, despite pressure on profits from competition and tariffs [12] - The outlook for the second half of the year is optimistic, with expectations of improved operational conditions as new products are launched [12]

据证券之星公开数据整理，近期莱茵生物（002166）发布2025年中报。截至本报告期末，公司营业总收 入8.37亿元，同比上升15.37%，归母净利润3811.0万元，同比下降41.27%。按单季度数据看，第二季度 营业总收入3.93亿元，同比上升2.19%，第二季度归母净利润731.51万元，同比下降80.8%。本报告期莱 茵生物应收账款上升，应收账款同比增幅达125.43%。 本次财报公布的各项数据指标表现一般。其中，毛利率23.57%，同比减17.59%，净利率5.22%，同比减 44.33%，销售费用、管理费用、财务费用总计1.13亿元，三费占营收比13.51%，同比减4.7%，每股净资 产4.11元，同比增1.38%，每股经营性现金流0.4元，同比增895.79%，每股收益0.05元，同比减44.44% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 7.25 亿 | 8.37亿 | 15.37% | | 归母净利润（元） | 6489.31万 | 3811万 | -41.27% | | 扣非净利润(元 ...

Core Insights - The company reported a revenue of 837 million yuan for the first half of 2025, representing a year-on-year growth of 15.37% [2] - The net profit attributable to shareholders was 38.11 million yuan, with a significant increase in operating cash flow net amounting to 295 million yuan, up 895.28% year-on-year [2] Revenue Breakdown - The natural sweetener business generated revenue of 397 million yuan, an increase of 7.67% year-on-year [2] - Tea extract revenue reached 108 million yuan, growing by 20.90% year-on-year [2] - Other extract products achieved revenue of 315 million yuan, reflecting a year-on-year growth of 26.33% [2] Product Performance - The core product, monk fruit extract, saw a sales volume increase of 20.35% and revenue growth of 63.61% year-on-year, demonstrating stable quality and supply capacity [2] - The company is collaborating with Jiangnan University to advance the industrialization of monk fruit glycoside synthesis technology, aiming to enhance its technological leadership in the industry [2] Innovation and Global Expansion - The company has successfully developed and supplied the new steviol glycoside RebM2, which is recognized as an ideal natural sweetener due to its superior taste and stability [3] - RebM2 has passed the US FDA GRAS certification, allowing entry into the high-end food and beverage market in the US, with domestic certification processes also progressing [3] - The company completed the upgrade of its Indiana factory, which will focus on the production of natural sweeteners and health product extracts, strengthening its global supply chain [3]

Group 1 - The company, Rhine Biotech (SZ 002166), announced that its seventh board meeting for 2025 was held on August 27, 2025, to review the special report on the use of raised funds for the first half of 2025 [1] - For the year 2024, the company's revenue composition was 97.47% from manufacturing and 2.53% from other industries [1]